LIVIVO - Search results -

Search results

Result 1 - 10 of total 30

Search options

Article: Natural killer cell-derived exosomes for cancer immunotherapy: innovative therapeutics art.

Hatami, Zahra / Hashemi, Zahra Sadat / Eftekhary, Mohamad / Amiri, Ala / Karpisheh, Vahid / Nasrollahi, Kaveh / Jafari, Reza

Cancer cell international

2023 Volume 23, Issue 1, Page(s) 157

Abstract: Chimeric antigen receptor natural killer cells (CAR-NK) promote off-the-shelf cellular therapy for solid tumors and malignancy.However,, the development of CAR-NK is due to their immune surveillance uncertainty and cytotoxicity challenge was restricted. ... ...

Abstract	Chimeric antigen receptor natural killer cells (CAR-NK) promote off-the-shelf cellular therapy for solid tumors and malignancy.However,, the development of CAR-NK is due to their immune surveillance uncertainty and cytotoxicity challenge was restricted. Natural killer cell-derived exosome (NK-Exo) combine crucial targeted cellular therapies of NK cell therapies with unique non-toxic Exo as a self-origin shuttle against cancer immunotherapy. This review study covers cytokines, adoptive (autologous and allogenic) NK immunotherapy, stimulatory and regulatory functions, and cell-free derivatives from NK cells. The future path of NK-Exo cytotoxicity and anti-tumor activity with considering non-caspase-independent/dependent apoptosis and Fas/FasL pathway in cancer immunotherapy. Finally, the significance and implication of NK-Exo therapeutics through combination therapy and the development of emerging approaches for the purification and delivery NK-Exo to severe immune and tumor cells and tissues were discussed in detail.
Language	English
Publishing date	2023-08-05
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2091573-1
ISSN	1475-2867
ISSN	1475-2867
DOI	10.1186/s12935-023-02996-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: The role of Th17 cells in the pathogenesis and treatment of breast cancer.

Karpisheh, Vahid / Ahmadi, Majid / Abbaszadeh-Goudarzi, Kazem / Mohammadpour Saray, Mehran / Barshidi, Asal / Mohammadi, Hamed / Yousefi, Mehdi / Jadidi-Niaragh, Farhad

Cancer cell international

2022 Volume 22, Issue 1, Page(s) 108

Abstract: Breast cancer is a severe problem worldwide due to an increase in mortality and prevalence among women. Despite early diagnostic procedures as well as advanced therapies, more investigation is required to find new treatment targets. Various factors and ... ...

Abstract	Breast cancer is a severe problem worldwide due to an increase in mortality and prevalence among women. Despite early diagnostic procedures as well as advanced therapies, more investigation is required to find new treatment targets. Various factors and mechanisms, such as inflammatory conditions, can play a crucial role in cancer progression. Among them, Th17 cells are identified as effective CD4
Language	English
Publishing date	2022-03-05
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2091573-1
ISSN	1475-2867
ISSN	1475-2867
DOI	10.1186/s12935-022-02528-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The role of SF3B1 and NOTCH1 in the pathogenesis of leukemia.

Abolhasani, Shiva / Hejazian, Seyyed Sina / Karpisheh, Vahid / Khodakarami, Atefeh / Mohammadi, Hamed / Gholizadeh Navashenaq, Jamshid / Hojjat-Farsangi, Mohammad / Jadidi-Niaragh, Farhad

IUBMB life

2022 Volume 75, Issue 3, Page(s) 257–278

Abstract: The discovery of new genes/pathways improves our knowledge of cancer pathogenesis and presents novel potential therapeutic options. For instance, splicing factor 3b subunit 1 (SF3B1) and NOTCH1 genetic alterations have been identified at a high frequency ...

Abstract	The discovery of new genes/pathways improves our knowledge of cancer pathogenesis and presents novel potential therapeutic options. For instance, splicing factor 3b subunit 1 (SF3B1) and NOTCH1 genetic alterations have been identified at a high frequency in hematological malignancies, such as leukemia, and may be related to the prognosis of involved patients because they change the nature of malignancies in different ways like mediating therapeutic resistance; therefore, studying these gene/pathways is essential. This review aims to discuss SF3B1 and NOTCH1 roles in the pathogenesis of various types of leukemia and the therapeutic potential of targeting these genes or their mutations to provide a foundation for leukemia treatment.
MeSH term(s)	Humans ; Leukemia/physiopathology ; Mutation ; Transcription Factors/genetics ; Transcription Factors/metabolism
Chemical Substances	NOTCH1 protein, human ; SF3B1 protein, human ; Transcription Factors
Language	English
Publishing date	2022-07-18
Publishing country	England
Document type	Review ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1492141-8
ISSN	1521-6551 ; 1521-6543
ISSN (online)	1521-6551
ISSN	1521-6543
DOI	10.1002/iub.2660
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1611: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.

Fathi, Mehrdad / Pustokhina, Inna / Kuznetsov, Sergey V / Khayrullin, Mars / Hojjat-Farsangi, Mohammad / Karpisheh, Vahid / Jalili, Ali / Jadidi-Niaragh, Farhad

IUBMB life

2021 Volume 73, Issue 5, Page(s) 726–738

Abstract: The importance of the tumor microenvironment in cancer progression has been well studied for many years. Immune checkpoint inhibitors (ICIs) are regarded as potential strategies in enhancing the immune responses in patients with cancer, particularly ... ...

Abstract	The importance of the tumor microenvironment in cancer progression has been well studied for many years. Immune checkpoint inhibitors (ICIs) are regarded as potential strategies in enhancing the immune responses in patients with cancer, particularly colorectal cancer (CRC). Notably, CRCs are extraordinarily heterogeneous and mostly are microsatellite-stable (MSS) or cold tumors, which means that the immune response is not usually as strong as that of foreign cells. T-cell immunoglobulin and ITIM domain (TIGIT) is a new immune checkpoint receptor overexpressed inside the CRC tumor-immune microenvironments. Moreover, several studies have shown that TIGIT in combination with other ICIs and/or conventional treatments, can lead to a robust anti-tumor response in CRC. This review looks deep inside TIGIT expression patterns, their various functions, and possible immunotherapy strategies to increase survival rates and decrease immune-related adverse events.
MeSH term(s)	Adenocarcinoma/immunology ; Adenocarcinoma/pathology ; Adenocarcinoma/therapy ; Amino Acid Motifs ; Animals ; Antigens, CD/immunology ; CRISPR-Cas Systems ; Colorectal Neoplasms/immunology ; Colorectal Neoplasms/pathology ; Colorectal Neoplasms/radiotherapy ; Colorectal Neoplasms/therapy ; Combined Modality Therapy ; Gastrointestinal Microbiome ; Gene Expression Regulation, Neoplastic ; Humans ; Immune Checkpoint Inhibitors ; Immune Checkpoint Proteins/immunology ; Immunotherapy/methods ; Mice ; Prognosis ; Protein Domains ; Receptors, Immunologic/antagonists & inhibitors ; Receptors, Immunologic/biosynthesis ; Receptors, Immunologic/deficiency ; Receptors, Immunologic/genetics ; Receptors, Immunologic/immunology ; Tumor Microenvironment
Chemical Substances	Antigens, CD ; CD96 antigen ; Immune Checkpoint Inhibitors ; Immune Checkpoint Proteins ; Receptors, Immunologic ; T cell Ig and ITIM domain protein, mouse ; TIGIT protein, human
Language	English
Publishing date	2021-03-30
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1492141-8
ISSN	1521-6551 ; 1521-6543
ISSN (online)	1521-6551
ISSN	1521-6543
DOI	10.1002/iub.2461
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1611: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: The role of regulatory T cells in the pathogenesis and treatment of prostate cancer

Karpisheh, Vahid / Mousavi, Seyedeh Mahboubeh / Sheykholeslami, Parinaz Naghavi / Fathi, Mehrdad / Saray, Mehran Mohammadpour / Aghebati-Maleki, Leili / Jafari, Reza / Zolbanin, Naime Majidi / Jadidi-Niaragh, Farhad

Life sciences. 2021 Jan. 18,

2021

Abstract: Despite developments in the treatment of various cancers, prostate cancer is one of the deadliest diseases known to men. Systemic therapies such as androgen deprivation, chemotherapy, and radiation therapy have not been very successful in treating this ... ...

Abstract	Despite developments in the treatment of various cancers, prostate cancer is one of the deadliest diseases known to men. Systemic therapies such as androgen deprivation, chemotherapy, and radiation therapy have not been very successful in treating this disease. Numerous studies have shown that there is a direct relationship between cancer progression and inhibition of anti-tumor immune responses that can lead to progression of various malignancies, including prostate cancer. Interestingly, CD4⁺CD25⁺FoxP3⁺ regulatory T cells significantly accumulate and increase in draining lymph nodes and PBMCs of patients with prostate cancer and other solid tumors. In vivo and in vitro studies have shown that Tregs can suppress anti-tumor responses, which is directly related to the increased risk of cancer recurrence. Tregs are essential for preserving self-tolerance and inhibiting extra immune responses harmful to the host. Since the tumor-related antigens are mainly self-antigens, Tregs could play a major role in tumor progression. Accordingly, it has discovered that prostate cancer patients with higher Tregs have poor prognosis and low survival rates. However, anti-tumor responses can be reinforced by suppression of Tregs with using monoclonal antibodies against CD25 and CTLA-4. Therefore, depleting Tregs or suppressing their functions could be one of the effective ways for prostate cancer immunotherapy. The purpose of this review is to investigate the role of Treg cells in the progression of prostate cancer and to evaluate effective strategies for the treatment of prostate cancer by regulating Treg cells.
Keywords	androgens ; cancer recurrence ; drug therapy ; immunotherapy ; lymph ; neoplasm progression ; prognosis ; prostatic neoplasms ; radiotherapy ; risk
Language	English
Dates of publication	2021-0118
Publishing place	Elsevier Inc.
Document type	Article
Note	NAL-light ; Pre-press version
ZDB-ID	3378-9
ISSN	1879-0631 ; 0024-3205
ISSN (online)	1879-0631
ISSN	0024-3205
DOI	10.1016/j.lfs.2021.119132
Database	NAL-Catalogue (AGRICOLA)

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Bonn / Germany

Z 73/732: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article: Combined inhibition of EZH2 and CD73 molecules by folic acid-conjugated SPION-TMC nanocarriers loaded with siRNA molecules prevents TNBC progression and restores anti-tumor responses

Adibfar, Sara / Masjedi, Ali / Nazer, Atefeh / Rashidi, Bentolhoda / Karpisheh, Vahid / Izadi, Sepideh / Hassannia, Hadi / Navashenaq, Jamshid Gholizadeh / Mohammadi, Hamed / Hojjat-Farsangi, Mohammad / Tarokhian, Hanieh / Jadidi-Niaragh, Farhad

Life sciences. 2022 Sept. 24,

2022

Abstract: Abnormal function or overexpression of CD73 and EZH2 within the tumor microenvironment and tumor cells enhances tumor growth and progression, and in many cases, causes drug resistance. Hence, it seems that silencing the expression of CD73 and EZH2 ... ...

Abstract	Abnormal function or overexpression of CD73 and EZH2 within the tumor microenvironment and tumor cells enhances tumor growth and progression, and in many cases, causes drug resistance. Hence, it seems that silencing the expression of CD73 and EZH2 molecules in breast cancer reduces cancer development and enhances anti-tumor immune responses. we used siRNA-loaded superparamagnetic iron oxide (SPIONs) nanoparticles (NPs) coated with trimethyl chitosan (TMC) and functionalized with folic acid for co-delivery of EZH2/CD73 siRNAs to 4 T1 murine cancer cells both in vitro and in vivo. Combination therapy markedly inhibited cancer cells' proliferation, migration, and viability and induced apoptosis in vitro. Moreover, in vivo administration of this combination therapy promoted tumor regression and induced anti-tumor immune responses. The findings indicated the CD73/EZH2 factors inhibition by SPION-TMC-FA NPs as a promising therapeutic strategy in breast cancer treatment.
Keywords	apoptosis ; breast neoplasms ; cancer therapy ; carcinogenesis ; chitosan ; drug resistance ; folic acid ; iron oxides ; mice ; nanocarriers ; nanoparticles ; remission ; viability
Language	English
Dates of publication	2022-0924
Publishing place	Elsevier Inc.
Document type	Article
Note	Pre-press version
ZDB-ID	3378-9
ISSN	1879-0631 ; 0024-3205
ISSN (online)	1879-0631
ISSN	0024-3205
DOI	10.1016/j.lfs.2022.121008
Database	NAL-Catalogue (AGRICOLA)

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Bonn / Germany

Z 73/732: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide.

Khodakarami, Atefeh / Kashani, Mahsa Afsari / Nazer, Atefeh / Kheshti, Armin Mahmoudsalehi / Rashidi, Bentolhoda / Karpisheh, Vahid / Masjedi, Ali / Abolhasani, Shiva / Izadi, Sepideh / Bagherifar, Rafieh / Hejazian, Seyyed Sina / Mohammadi, Hamed / Movassaghpour, AliAkbar / Feizi, Abbas Ali Hosseinpour / Hojjat-Farsangi, Mohammad / Jadidi-Niaragh, Farhad

Cell communication and signaling : CCS

2023 Volume 21, Issue 1, Page(s) 188

Abstract: Background: Targeting influential factors in resistance to chemotherapy is one way to increase the effectiveness of chemotherapeutics. The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway overexpresses in chronic lymphocytic leukemia (CLL) ... ...

Abstract	Background: Targeting influential factors in resistance to chemotherapy is one way to increase the effectiveness of chemotherapeutics. The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway overexpresses in chronic lymphocytic leukemia (CLL) cells and appears to have a significant part in their survival and chemotherapy resistance. Here we produced novel nanoparticles (NPs) specific for CD20-expressing CLL cells with simultaneous anti-Nrf2 and cytotoxic properties. Methods: Chitosan lactate (CL) was used to produce the primary NPs which were then respectively loaded with rituximab (RTX), anti-Nrf2 Small interfering RNA (siRNAs) and Cyclophosphamide (CP) to prepare the final version of the NPs (NP-Nrf2_siRNA-CP). All interventions were done on both peripheral blood mononuclear cells (PBMCs) and bone marrow mononuclear cells (BMNCs). Results: NP-Nrf2_siRNA-CP had satisfying physicochemical properties, showed controlled anti-Nrf2 siRNA/CP release, and were efficiently transfected into CLL primary cells (both PBMCs and BMNCs). NP-Nrf2_siRNA-CP were significantly capable of cell apoptosis induction and proliferation prevention marked by respectively decreased and increased anti-apoptotic and pro-apoptotic factors. Furthermore, use of anti-Nrf2 siRNA was corresponding to elevated sensitivity of CLL cells to CP. Conclusion: Our findings imply that the combination therapy of malignant CLL cells with RTX, CP and anti-Nrf2 siRNA is a novel and efficient therapeutic strategy that was capable of destroying malignant cells. Furthermore, the use of NPs as a multiple drug delivery method showed fulfilling properties; however, the need for further future studies is undeniable. Video Abstract.
MeSH term(s)	Humans ; Rituximab/pharmacology ; Rituximab/metabolism ; Rituximab/therapeutic use ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/metabolism ; Leukocytes, Mononuclear/metabolism ; Cyclophosphamide/pharmacology ; Cyclophosphamide/therapeutic use ; Cyclophosphamide/metabolism ; RNA, Small Interfering/metabolism ; Nanoparticles
Chemical Substances	Rituximab (4F4X42SYQ6) ; chitosan lactate ; Cyclophosphamide (8N3DW7272P) ; RNA, Small Interfering
Language	English
Publishing date	2023-08-01
Publishing country	England
Document type	Video-Audio Media ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2126315-2
ISSN	1478-811X ; 1478-811X
ISSN (online)	1478-811X
ISSN	1478-811X
DOI	10.1186/s12964-023-01213-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Retraction Note: Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model.

Barshidi, Asal / Karpisheh, Vahid / Noukabadi, Fatemeh Karimian / Kiani, Fariba Karoon / Mohammadi, Mohammad / Afsharimanesh, Negin / Ebrahimi, Farbod / Kiaie, Seyed Hossein / Navashenaq, Jamshid Gholizadeh / Hojjat-Farsangi, Mohammad / Zolbanin, Naime Majidi / Mahmoodpoor, Ata / Hassannia, Hadi / Nami, Sanam / Jalali, Pooya / Jafari, Reza / Jadidi-Niaragh, Farhad

Pharmaceutical research

2023 Volume 41, Issue 2, Page(s) 407–408

Language	English
Publishing date	2023-12-26
Publishing country	United States
Document type	Retraction of Publication
ZDB-ID	843063-9
ISSN	1573-904X ; 0724-8741 ; 0739-0742
ISSN (online)	1573-904X
ISSN	0724-8741 ; 0739-0742
DOI	10.1007/s11095-023-03647-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1937: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: The molecular biology and therapeutic potential of Nrf2 in leukemia.

Khodakarami, Atefeh / Adibfar, Sara / Karpisheh, Vahid / Abolhasani, Shiva / Jalali, Pooya / Mohammadi, Hamed / Gholizadeh Navashenaq, Jamshid / Hojjat-Farsangi, Mohammad / Jadidi-Niaragh, Farhad

Cancer cell international

2022 Volume 22, Issue 1, Page(s) 241

Abstract: NF-E2-related factor 2 (Nrf2) transcription factor has contradictory roles in cancer, which can act as a tumor suppressor or a proto-oncogene in different cell conditions (depending on the cell type and the conditions of the cell environment). Nrf2 ... ...

Abstract	NF-E2-related factor 2 (Nrf2) transcription factor has contradictory roles in cancer, which can act as a tumor suppressor or a proto-oncogene in different cell conditions (depending on the cell type and the conditions of the cell environment). Nrf2 pathway regulates several cellular processes, including signaling, energy metabolism, autophagy, inflammation, redox homeostasis, and antioxidant regulation. As a result, it plays a crucial role in cell survival. Conversely, Nrf2 protects cancerous cells from apoptosis and increases proliferation, angiogenesis, and metastasis. It promotes resistance to chemotherapy and radiotherapy in various solid tumors and hematological malignancies, so we want to elucidate the role of Nrf2 in cancer and the positive point of its targeting. Also, in the past few years, many studies have shown that Nrf2 protects cancer cells, especially leukemic cells, from the effects of chemotherapeutic drugs. The present paper summarizes these studies to scrutinize whether targeting Nrf2 combined with chemotherapy would be a therapeutic approach for leukemia treatment. Also, we discussed how Nrf2 and NF-κB work together to control the cellular redox pathway. The role of these two factors in inflammation (antagonistic) and leukemia (synergistic) is also summarized.
Language	English
Publishing date	2022-07-29
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2091573-1
ISSN	1475-2867
ISSN	1475-2867
DOI	10.1186/s12935-022-02660-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Combined inhibition of EZH2 and CD73 molecules by folic acid-conjugated SPION-TMC nanocarriers loaded with siRNA molecules prevents TNBC progression and restores anti-tumor responses.

Adibfar, Sara / Masjedi, Ali / Nazer, Atefeh / Rashidi, Bentolhoda / Karpisheh, Vahid / Izadi, Sepideh / Hassannia, Hadi / Gholizadeh Navashenaq, Jamshid / Mohammadi, Hamed / Hojjat-Farsangi, Mohammad / Tarokhian, Hanieh / Jadidi-Niaragh, Farhad

Life sciences

2022 Volume 309, Page(s) 121008

Abstract: Background: Abnormal function or overexpression of CD73 and EZH2 within the tumor microenvironment and tumor cells enhances tumor growth and progression, and in many cases, causes drug resistance. Hence, it seems that silencing the expression of CD73 ... ...

Abstract	Background: Abnormal function or overexpression of CD73 and EZH2 within the tumor microenvironment and tumor cells enhances tumor growth and progression, and in many cases, causes drug resistance. Hence, it seems that silencing the expression of CD73 and EZH2 molecules in breast cancer reduces cancer development and enhances anti-tumor immune responses. Methods: we used siRNA-loaded superparamagnetic iron oxide (SPIONs) nanoparticles (NPs) coated with trimethyl chitosan (TMC) and functionalized with folic acid for co-delivery of EZH2/CD73 siRNAs to 4 T1 murine cancer cells both in vitro and in vivo. Results: Combination therapy markedly inhibited cancer cells' proliferation, migration, and viability and induced apoptosis in vitro. Moreover, in vivo administration of this combination therapy promoted tumor regression and induced anti-tumor immune responses. Discussion: The findings indicated the CD73/EZH2 factors inhibition by SPION-TMC-FA NPs as a promising therapeutic strategy in breast cancer treatment.
MeSH term(s)	Humans ; Mice ; Animals ; RNA, Small Interfering/genetics ; Chitosan ; Folic Acid/pharmacology ; Triple Negative Breast Neoplasms ; Nanoparticles ; Magnetic Iron Oxide Nanoparticles ; Cell Line, Tumor ; Tumor Microenvironment ; Enhancer of Zeste Homolog 2 Protein/genetics
Chemical Substances	RNA, Small Interfering ; Chitosan (9012-76-4) ; Folic Acid (935E97BOY8) ; EZH2 protein, human (EC 2.1.1.43) ; Enhancer of Zeste Homolog 2 Protein (EC 2.1.1.43)
Language	English
Publishing date	2022-09-27
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	3378-9
ISSN	1879-0631 ; 0024-3205
ISSN (online)	1879-0631
ISSN	0024-3205
DOI	10.1016/j.lfs.2022.121008
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uc I Zs.368: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito